1. Home
  2. Directory
  3. New York
  4. Dobbs Ferry
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1609292739

MANSI SHAH SINGH DO
Prescription History 1609292739
Psychiatry & Neurology - Child & Adolescent Psychiatry in Dobbs Ferry, NY

NPI Status: Active since March 13, 2014

Contact Information

1 ECHO HL
DOBBS FERRY, NY
ZIP 10522
Phone: (914) 693-0600

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MANSI SHAH SINGH DO, an active Child & Adolescent Psychiatry specialist practicing in Dobbs Ferry, NY. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 61 documented patient claims. Among these therapy options, the most frequently utilized medication is Risperidone, which accounts for 34 claims alone.

Medication Index

B
Q
R
No matching medications currently found on file.

Benztropine Mesylate

Generic Formulation: Benztropine MesylateSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 435
NY State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills56.2
Peer Average Days Supply1,596
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $170.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.34

State Avg Cost Per Claim

$12.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.

Therapeutic Applications

Benztropine is used to treat symptoms of Parkinson's disease or involuntary movements due to the side effects of certain psychiatric drugs (antipsychotics such as chlorpromazine/haloperidol). Benztropine belongs to a class of medication called anticholinergics that work by blocking a certain natural substance (acetylcholine). This helps decrease muscle stiffness, sweating, and the production of saliva, and helps improve walking ability in people with Parkinson's disease. Anticholinergics can stop severe muscle spasms of the back, neck, and eyes that are sometimes caused by psychiatric drugs. It can also decrease other side effects such as muscle stiffness/rigidity (extrapyramidal signs-EPS). It is not helpful in treating movement problems caused by tardive dyskinesia and may worsen them. Benztropine should not be used by children younger than 3 years.

Quetiapine Fumarate

Generic Formulation: Quetiapine FumarateSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NY State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills72.4
Peer Average Days Supply2,058
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $216.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.02

State Avg Cost Per Claim

$33.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

Therapeutic Applications

This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. It may also improve your mood, sleep, appetite, and energy level. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur.

Risperidone

Generic Formulation: RisperidoneSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 1,020
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills62.2
Peer Average Days Supply1,744
Conservative Utilization

This provider writes prescriptions for this formulation 38.2% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $392.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.55

State Avg Cost Per Claim

$14.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.

Therapeutic Applications

Risperidone is used to treat a certain mental/mood disorder called schizophrenia. This medication can decrease hallucinations, help you to think more clearly and positively about yourself, feel less agitated, and take a more active part in everyday life. Risperidone is an antipsychotic drug (atypical type). It works by helping to restore the balance of certain natural substances in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MANSI SHAH SINGH DO provides transparency into local medical care patterns within Dobbs Ferry, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Child & Adolescent Psychiatry** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.